HER2/Neu GP2 vaccine (Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology)

Initial analysis of FLAMINGO-01 trial reveals 46% of screened patients carry at least one HLA-A*02 allele, a crucial factor for GLSI-100 breast cancer vaccine treatment.

Greenwich LifeSciences broadens its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, by adding new clinical sites in the U.S. and Europe.

MAIA Biotechnology's lead candidate, THIO, is currently in Phase II clinical trials, evaluating its potential in treating patients with non-small cell lung cancer.

Greenwich LifeSciences partners with Gruppo Italiano Mammella (GIM) to expand its Phase III FLAMINGO-01 trial in Italy.

Greenwich LifeSciences' Flamingo-01 Phase III trial, evaluating GLSI-100 for breast cancer recurrence prevention, has been approved for expansion into Europe, including Spain, France, Germany, Italy, and Poland.